Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

Journal of Clinical Oncology

Volumn 15, Issue 6, 1997, Pages 2183-2193

  ten Bokkel Huinink, Wim ^a   Gore, Martin ^a   Carmichael, James ^a   Gordon, Alan ^a   Malfetano, John ^a   Hudson, Ian ^a   Broom, Colin ^a   Scarabelli, Claudio ^a   Davidson, Neville ^a   Spanczynski, Marek ^a   Bolis, Giorgio ^a   Malmström, Henric ^a   Coleman, Robert ^a   Fields, Scott C ^a   Heron, Jean Francois ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE; DOUBLE STRANDED DNA; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DNA REPLICATION; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NEUTROPENIA; OVARY CANCER; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; TREATMENT PLANNING;

EID: 0030900145     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.6.2183     Document Type: Article

References (25)

1. Young RC, Perez CA, Hoskins WJ: Cancer of the ovary, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 4). Philadelphia, PA, Lippincott, 1993, pp 1126-1263
2. American Cancer Society: Cancer Facts and Figures - 1996. Atlanta, GA, American Cancer Society Inc, 1996
3. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Engl J Med 334:1-6, 1996
4. Cannistra SA: Cancer of the ovary. N Eng J Med 329:1550-1559, 1993
5. Ozols RF: Treatment of ovarian cancer: Current status. Semin Oncol 21:1-9, 1994 (suppl 6)
6. Neijt JP, ten Bokkel Huinink WW, van Der Berg M, et al: Longterm survival in ovarian cancer. Eur J Can 27:1367-1372, 1991
7. Vergote I, Himmelmann A, Frankendal B, et al: Hexamethymelamine as second-line therapy in platinum-resistant ovarian cancer. Gynecol Oncol 47:282-286, 1992
8. Baker TR, Piver MS, Hempling RE: The addition of etoposide and ifosfamide to cisplatin as second-line therapy in ovarian carcinoma. Eur J Gynaecol Oncol 14:18-22, 1993
9. Hoskins P, Swenerton KD: Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 12:60-63, 1994
10. Einzig AI, Wiernik PH, Sasloff J, et al: Phase II study and long term follow-up of patients treated with Taxol for advanced ovarian cancer adenocarcinoma. J Clin Oncol 10:1748-1753, 1992
11. McGuire WP, Rowinsky EK, Rosenshein NB, et al: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 11:273-279, 1989
12. Thigpen JT, Blessing JA, Ball H, et al: Phase II trial in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study. J Clin Oncol 12:1748-1753, 1994
13. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
14. Hertzberg RP, Caranfa MJ, Hecht SM: On the mechanism of topoisomerase 1 inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex. Biochemistry 28:4629-4638, 1989
15. Hsiang YH, Lihou MG, Liu LF: Arrest of replicating forks by drug-stabilized topoisomerase 1-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49:5077-5082, 1989
16. Burris HA III, Hanauske AR, Johnson RK, et al: Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 84:1816-1820, 1992
17. Houghton PJ, Cheshire PJ, Myers L, et al: Evaluation of 9-dimethylaminomethyl-10-hydroxycampothecin against xenogratts derived from adult and childhood solid tumors. Can Chemother Pharmacol 31:229-239, 1992
18. Rowinsky EK, Grochow, LB, Hendricks, et al: Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 10:647-656, 1992
19. Verweij J, Lund B, Beijnen J, et al: Phase I and pharmacokinectic study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 4:673-678, 1993
20. Saltz L, Sirott M, Young C, et al: Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors with attempt at dose intensification using recombinant granulocyte colony stimulating factor. J Natl Cancer Inst 85:1499-1507, 1993
21. Kudelka A, Edwards C, Freedman R, et al: An open phase II study to evaluate the efficacy and toxicity of topotecan administered as 5 daily infusions every 21 days to women with advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol 12:A821, 1993 (abstr)
22. Armstrong D, Rowinsky E, Donehower R, et al: A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer. Proc Am Soc Clin Oncol 14:A769, 1995 (abstr)
23. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization, 1979
24. Van der Burg M, Am H, Van lent M, et al: Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy. Eur J Cancer 27:248-250, 1991
25. Markman M, Berek JS, Blessing JA, et al: Characteristics of patients with small volume residual ovarian cancer unresponsive to cisplatin-based IP chemotherapy: Lessons learned from a Gynecologic Oncology Group phase II trial of IP cisplatin and recombinant α-interferon. Gynecol Oncol 45:3-8, 1992